Geneos Wealth Management Inc. Increases Stake in Danaher Co. (NYSE:DHR)

Geneos Wealth Management Inc. increased its holdings in Danaher Co. (NYSE:DHR) by 2.4% in the fourth quarter, Holdings Channel reports. The fund owned 16,713 shares of the conglomerate’s stock after purchasing an additional 399 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Danaher were worth $3,837,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. Eclectic Associates Inc. ADV lifted its position in shares of Danaher by 8.7% in the 4th quarter. Eclectic Associates Inc. ADV now owns 964 shares of the conglomerate’s stock worth $221,000 after purchasing an additional 77 shares during the period. CX Institutional raised its stake in Danaher by 2.1% in the fourth quarter. CX Institutional now owns 2,970 shares of the conglomerate’s stock worth $682,000 after buying an additional 62 shares in the last quarter. Manitou Investment Management Ltd. raised its stake in Danaher by 0.5% in the fourth quarter. Manitou Investment Management Ltd. now owns 92,685 shares of the conglomerate’s stock worth $21,276,000 after buying an additional 481 shares in the last quarter. Hengehold Capital Management LLC lifted its holdings in Danaher by 30.3% during the fourth quarter. Hengehold Capital Management LLC now owns 2,340 shares of the conglomerate’s stock worth $537,000 after buying an additional 544 shares during the period. Finally, True North Advisors LLC boosted its position in Danaher by 70.8% during the 4th quarter. True North Advisors LLC now owns 1,720 shares of the conglomerate’s stock valued at $395,000 after acquiring an additional 713 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DHR has been the topic of a number of recent research reports. Raymond James dropped their price objective on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. Barclays cut their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Citigroup decreased their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a report on Thursday, October 31st. Finally, Royal Bank of Canada decreased their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average target price of $285.55.

Danaher Stock Up 0.1 %

DHR stock opened at $245.95 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm’s fifty day simple moving average is $235.33 and its 200-day simple moving average is $253.45. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The company has a market capitalization of $177.65 billion, a P/E ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.